Tscan Therapeutics, Inc. (TCRX) — 8-K Filings

8-K Filings (17)

• 8-K Filing — May 6, 2026
• TScan Therapeutics Director Departs, Becomes Senior Advisor — Apr 2, 2026 Risk: low
  TScan Therapeutics, Inc. announced on March 31, 2026, the departure of Dr. Steven D. Altschuler from its Board of Directors. The company also appointed Dr. Alts
• 8-K Filing — Nov 26, 2025
• TScan Therapeutics Files 8-K on Exit Activities — Nov 3, 2025 Risk: medium
  TScan Therapeutics, Inc. filed an 8-K on November 3, 2025, reporting on cost associated with exit or disposal activities, Regulation FD disclosure, and other ev
• TScan Therapeutics Files 8-K — Sep 9, 2025 Risk: low
  TScan Therapeutics, Inc. filed an 8-K on September 9, 2025, to report information under Regulation FD and to file financial statements and exhibits. The filing
• TScan Therapeutics Announces Board and Executive Changes — Aug 20, 2025 Risk: medium
  TScan Therapeutics, Inc. announced on August 14, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departu
• TScan Therapeutics Files 8-K on Shareholder Votes — Jul 2, 2025 Risk: low
  TScan Therapeutics, Inc. filed an 8-K on July 2, 2025, reporting on matters submitted to a vote of security holders as of June 30, 2025. The filing details the
• TScan Therapeutics Merges with Enliven Therapeutics, Renames Company — Dec 26, 2024 Risk: medium
  On December 26, 2024, TScan Therapeutics, Inc. announced the closing of its previously disclosed merger agreement with Enliven Therapeutics, Inc. The transactio
• TScan Therapeutics Terminates Agreement, Incurs Obligation — Dec 23, 2024 Risk: medium
  TScan Therapeutics, Inc. announced on December 20, 2024, the termination of a material definitive agreement and the creation of a direct financial obligation. T
• Enovis to Acquire TScan Therapeutics for $1.1B — Dec 10, 2024 Risk: medium
  TScan Therapeutics, Inc. announced on December 9, 2024, that it has entered into a definitive agreement to be acquired by Enovis Corporation for approximately $
• TScan Therapeutics Reports Unregistered Equity Sale — Nov 21, 2024 Risk: medium
  TScan Therapeutics, Inc. reported an unregistered sale of equity securities on November 15, 2024. The company, incorporated in Delaware, filed an 8-K form with
• TScan Therapeutics Enters Material Definitive Agreement — Nov 1, 2024 Risk: medium
  TScan Therapeutics, Inc. announced on October 28, 2024, that it entered into a material definitive agreement. The filing does not provide specific details about
• Armata to Acquire TScan Therapeutics for $1.1B — Jun 14, 2024 Risk: medium
  TScan Therapeutics, Inc. announced on June 12, 2024, that it has entered into a definitive agreement to be acquired by Armata Pharmaceuticals, Inc. for approxim
• TScan Therapeutics Enters Material Agreement — Apr 17, 2024 Risk: medium
  TScan Therapeutics, Inc. announced on April 16, 2024, that it entered into a Material Definitive Agreement. The company also reported on its Results of Operatio
• TScan Therapeutics Files 8-K Report — Apr 16, 2024 Risk: low
  On April 16, 2024, TScan Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements, with no specific material
• TScan Therapeutics Files 8-K — Apr 8, 2024 Risk: low
  TScan Therapeutics, Inc. filed an 8-K on April 8, 2024, to report other events and financial statements. The filing does not contain specific financial figures
• TScan Therapeutics Names Gavin MacBeath CEO; David Southwell Becomes Executive Chair — Jan 29, 2024
  TScan Therapeutics, Inc. (TCRX) filed an 8-K on January 29, 2024, reporting that its President and CEO, David Southwell, will transition to a new role as Execut

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX